Screening for Alzheimer's Disease Studies

(TRAVELLER Trial)

Recruiting at 139 trial locations

Overseen By Reference Study ID Number: WP45722 https://forpatients.roche.com/

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: Hoffmann-La Roche

Disqualifiers: Neurological conditions, CNS trauma, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

13000 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Who Is on the Research Team?

Clinical Trials

Principal Investigator

Hoffmann-La Roche

Are You a Good Fit for This Trial?

This pre-screening study is for individuals who may have Alzheimer's disease or cognitive impairment and are interested in participating in future Roche interventional studies. Specific eligibility criteria details are not provided.

Inclusion Criteria

Report of objective or subjective memory concerns (by the participant and/or their informant) within the last year with or without a previous clinical diagnosis of MCI or dementia due to AD.

Exclusion Criteria

Visual or auditory impairment that would prevent them from performing the cognitive assessments (eyeglasses and hearing aids are permitted)

History of severe, clinically significant central nervous system trauma

Any serious medical condition that precludes a participant's safe participation and completion of a clinical study

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Assessment

Participants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT)

1-2 weeks

Follow-up

Participants are monitored for safety and effectiveness after assessment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• No Intervention

Trial Overview The trial does not involve any interventions. It is designed to assess the suitability of participants for upcoming Roche Alzheimer's disease research trials through a screening process.

How Is the Trial Designed?

Group I: Screening Arm Experimental Treatment 1 Intervention

Participants will be assessed for their concentration of pTau217 in blood and cognitive score in the International Shopping List Test (ISLT).

Who Is Running the Clinical Trial?

Hoffmann-La Roche

Lead Sponsor

Trials

2,482

Recruited

1,107,000+

Headquarters

Basel, Switzerland

Known For

Precision medicine

Top Products

Avastin, Herceptin, Rituxan, Accu-Chek

Dr. Levi Garraway

Hoffmann-La Roche

Chief Medical Officer since 2019

MD from the University of Basel

Dr. Thomas Schinecker

Hoffmann-La Roche

Chief Executive Officer since 2023

PhD in Molecular Biology from New York University